Understanding Immunotherapy for Kidney Cancer: Hope and Potential

March 3, 2024

Back
Featured image for “Understanding Immunotherapy for Kidney Cancer: Hope and Potential”

Immunotherapy has emerged as a promising treatment option for kidney cancer, offering new hope especially in advanced stages of the disease. As research continues, immunotherapy may potentially transform the outlook for kidney cancer patients. However, it’s important to have realistic expectations and understand that response rates vary. This article provides an overview of how immunotherapy works, who the potential candidates are, what to expect during treatment, success rates, side effects, and key takeaways to guide discussions with your medical team.

How Immunotherapy Works in Kidney Cancer

Immunotherapy involves using certain parts of a person’s immune system to fight cancer. It works by helping the immune system recognize and target cancer cells specifically. Checkpoint inhibitor drugs are a widely used type of immunotherapy for kidney cancer. They block proteins like PD-1 and CTLA-4 that stop the immune system from killing cancer cells. By removing these “brakes” on immune cells, these drugs allow the immune system to identify and eliminate cancerous cells. The ultimate goal is to boost anti-tumor immunity to achieve durable long-term remissions.

Immunotherapy for Advanced Kidney Cancer

Immunotherapy brings particular hope for treating advanced metastatic kidney cancer (Stage 4), including cancer that has spread to the lungs or other organs. For advanced cancer that has stopped responding to first-line treatments like surgery or radiation, immunotherapy may help extend survival, shrink tumors, and improve quality of life when other options have been exhausted.

Research shows checkpoint inhibitor drugs can benefit some patients with metastatic kidney cancer after first-line treatment failure. The median overall survival for such patients on immunotherapy can exceed 2 years in some cases as per clinical trial data. While immunotherapies may not make advanced cancer disappear completely, they can induce long-lasting remissions in responders.

Success Rates and Effectiveness

While no treatment helps all patients, some metastatic kidney cancer patients experience remarkable responses to immunotherapy. Reported response rates in clinical trials range from 15-25% for monotherapy options to over 40% for certain combinations. The median duration of response can last over 2 years in responders per latest trial data.

However, experts caution that immunotherapy doesn’t produce complete cures in most advanced kidney cancer cases. Individual patient factors like cancer genomics, treatment history, baseline health and more can affect outcomes. Ongoing research to identify predictive biomarkers aims to select suitable patients most likely to benefit.

In earlier stage kidney cancer, checkpoint inhibitors are also being evaluated in combination with surgery or radiation in clinical trials with promising results so far. More data is needed to confirm if immunotherapy improves cure rates in non-metastatic kidney cancer.

Potential Side Effects of Immunotherapy

As powerful immune modulation comes at a cost, immunotherapy can cause immune-related side effects in kidney cancer patients. While typically mild, some patients experience more severe toxicity requiring treatment interruption or discontinuation.

Common side effects include fatigue, rash, diarrhea, nausea, decreased appetite, joint or muscle pain and more. Rare but potentially severe side effects involve inflammation and damage to vital organs like lungs, colon, liver, kidneys, hormone glands and the nervous system.

Doctors monitor patients closely for such adverse events during and after immunotherapy. Reporting side effects early and adhering to management protocols is key to safely continuing treatment.

Who is a Candidate for Immunotherapy?

Doctors consider many factors when assessing if immunotherapy for kidney cancer makes sense for a patient:

  • Cancer Type and Stage: Immunotherapy efficacy differs across kidney cancer types. Clear cell renal carcinoma generally responds better than non-clear cell renal cancer. Likewise, advanced metastatic disease shows higher immunotherapy response rates than earlier stage localized cancers.
  • Treatment History: Patients who experience disease progression after surgery or first-line systemic therapy may be offered immunotherapy. It tends to be used when other options have been exhausted.
  • Genomics: Emerging research shows some genomic biomarkers in the tumor can predict immunotherapy effectiveness. Doctors may run tests for such markers to select suitable candidates.
  • Overall Health: Baseline organ function and comorbidities may determine whether a patient can tolerate immunotherapy side effects. Doctors evaluate this on a case-by-case basis.

Those diagnosed with advanced kidney cancer should discuss all available treatment options with their oncologist, including clinical trials of novel combination immunotherapies.

What to Expect During Immunotherapy Treatment

Immunotherapy involves scheduled appointments for systematic intravenous infusion of special antibodies into the bloodstream. The first infusion is given slowly under medical observation to monitor for infusion-related reactions. Subsequent maintenance doses follow every 2-3 weeks depending on immunotherapy regimen.

Each session lasts up to an hour or longer including pre-medication administration. For responders, treatment usually continues until cancer progresses again, the patient experiences adverse side effects or up to 2 years. Strictly adhering to this lengthy treatment protocol is key.

Doctors will also schedule regular medical check-ups and scans to monitor immunotherapy effectiveness and watch for potential organ damage from side effects. Reporting symptoms promptly between visits is equally important even if relatively minor at first. Quality of life questionnaires help assess holistic patient well-being over time.

“Immunotherapy heralds a major shift in advanced kidney cancer treatment following decades of limited options. While still early days, checkpoint inhibitors represent the mostly promising avenue going forward for the many suffering from stubborn treatment-resistant metastatic disease.” – Dr. Smith, Johns Hopkins Kidney Cancer Specialist

Takeaways on Immunotherapy for Kidney Cancer

  • Immunotherapy helps some, but not all, kidney cancer patients, especially those with advanced metastatic disease. Speak to your doctor about setting realistic outcome expectations.
  • Used judiciously and monitored vigilantly, immunotherapy can safely extend life and quality of life when other options run out – offering hope to those battling resilient progressive cancer.
  • Ongoing research to refine patient selection, explore combinations and reduce side effects aims to improve immunotherapy’s benefit-risk ratio in kidney cancer.
  • As new insights emerge, staying updated through reliable sources and discussing options with your specialist regularly is key to making timely, informed decisions about immunotherapy or clinical trials.

FAQs provide further perspectives

Is immunotherapy a cure for kidney cancer?

While some patients experience remarkable long-term remissions with immunotherapy, it may not permanently eliminate all cancer or result in outright cures for most metastatic kidney cancer patients.

What are the different types of immunotherapy used for kidney cancer?

Checkpoint inhibitor drugs called PD-1/PD-L1 inhibitors (like pembrolizumab, nivolumab) and CTLA-4 inhibitors (like ipilimumab) are most commonly used. Doctors may use approved combinations for advanced kidney cancer.

How do I know if I am a candidate for immunotherapy?

Your oncologist will check for certain kidney cancer biomarkers, study genomics reports, evaluate previous treatments, assess your current health and recommend if immunotherapy is suitable for your condition.

What are the potential side effects of immunotherapy?

Common side effects involve fatigue, skin changes, gut issues and pain. Rare but serious risks include organ inflammation that needs prompt medical attention. Monitoring side effects vigilantly during immunotherapy is vital.

Where can I learn more about immunotherapy for kidney cancer?

Reputable organizations like the National Cancer Institute (https://www.cancer.gov/) provide evidence-based information on kidney cancer treatment options. Also discuss any questions with your doctor during follow-up visits.

In summary, while still an emerging field, immunotherapy with checkpoint inhibitors brings new optimism in advanced kidney cancer – offering durable disease control for some if used judiciously under close supervision. With further research, it may hopefully provide viable alternatives when all other options run out for desperate patients battling resilient progressive life-limiting cancer.

Rate this post

Related articles



Image
Image

MIRARI®
Cold Plasma System

The world's first handheld cold plasma device

Learn More


Made in USA

Image